Interferon-gamma plays a crucial role in driving crypt hyperplasia, a hallmark of celiac disease and other inflammatory intestinal disorders. Crypt hyperplasia refers to the abnormal elongation and proliferation of epithelial crypts in the intestinal lining, which is commonly observed in active celiac disease.
Interferon-gamma plays a crucial role in driving crypt hyperplasia, a hallmark of celiac disease and other inflammatory intestinal disorders. Crypt hyperplasia refers to the abnormal elongation and proliferation of epithelial crypts in the intestinal lining, which is commonly observed in active celiac disease.
Research using mass spectrometry-based tissue proteomics revealed strong interferon-gamma activity in the epithelial crypt zone of patients with active celiac disease. This was evidenced by increased expression of major histocompatibility complex (MHC) molecules and decreased levels of proteins involved in fatty acid metabolism, indicating significant molecular changes in the intestinal epithelium.
To further investigate, experiments in wild-type mice demonstrated that administration of interferon-gamma reproduced the morphological and molecular features of crypt hyperplasia, confirming its role in driving this pathological process. Importantly, mice lacking interferon-gamma receptors specifically in gut epithelial cells did not develop crypt hyperplasia when exposed to interferon-gamma, providing direct evidence that interferon-gamma acts on epithelial cells to induce these changes.
Overall, interferon-gamma is a direct driver of crypt hyperplasia in celiac disease, highlighting its critical role in the disease's pathogenesis. It may also play a similar role in other inflammatory intestinal disorders involving interferon-gamma signaling, making it a potential therapeutic target for these conditions.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.